Age-related macular degeneration, a leading cause of blindness, is caused by an abnormal growth of the vessels beneath the retina. Ranibizumab (Lucentis) is a new drug that inhibits the growth of new vessels and has recently been approved by FDA for treating this condition. This study is carried out to evaluate the changes in retinal function after an injection of ranibizumab.
The functional changes of the retina can be recorded by an electroretinography (ERG).
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
25
A single dose of 0.5 mg ranibizumab injected intravitreally.
Department of Ophthalmology, Faculty of Medicine, Prince of Songkla University
Hat Yai, Changwat Songkhla, Thailand
Height (Amplitude) of Multifocal ERG Signal
Comparing the response in hight of signal amplitude at 3 months after treatment with baseline data.
Time frame: baseline, 3 months
Time to Response (Implicit Time) of Multifocal ERG Signal
Comparing the change in time of signal response (implicit time) at 3 months after treatment with baseline data.
Time frame: baseline, 3 months
Postoperative Complication
For instance, Endophthalmitis, retinal detachment
Time frame: 1 month
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.